[Abstract] Dengue is a global public health threat caused by infection with any of the 4 related dengue virus serotypes (DENV1-4). Clinical manifestations range from self-limiting febrile illness, known as dengue fever (DF), to life-threatening severe diseases, such as dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS). Most cases of DHF/DSS are associated with secondary heterotypic infections through a phenomenon that is described as antibody-dependent enhancement of infection The inbred mouse model system allows experimental variability to be minimized, and genetically engineered mouse models enable to reproduce some aspects of dengue clinical symptoms in the animals. A past study showed that AG129 mice (lacking type I and II IFN receptors) infected with a DENV2 clinical isolate succumbed to infection with signs of paralysis, a condition of central nervous system involvement that is rare in human cases (Shresta et al., 2004) . Alternatively, mouse-adapted DENV2 strains that can induce human DHF/DSS-like diseases in AG129 mice were generated and have been used for dengue research (Shresta et al., 2006; Zellweger et al., 2010) . Although the use of the mouse-adapted strains is valuable for some aspects of DENV pathogenesis studies and potential therapeutic drug testing, one considerable limitation is the variable pathogenesis depending on the serotype/genotype, and adaptation of virus in mouse might alter tissue tropism. Recently, we developed new mouse models of clinical isolates DENV1 and DENV2; the mice succumbed to infection with signs
2 of severe dengue symptoms (Watanabe et al., 2016) . Non-lethal infection with clinical isolates becomes lethal accompanied with high levels of viremia and cytokine production in the presence of DENV antibodies (Abs) (ADE condition) in AG129 mice, suggesting that this system enables to extend the use of clinical DENV isolates for the study of Ab-mediated DENV pathogenesis and the evaluation of antidengue candidates. 
Materials and Reagents

The virus titer obtained from C6/36 cells differs among virus strains. Thus, optimization of culture condition such as multiplicity of infection (MOI) of virus inoculum or timing of virus collection is
needed to obtain enough virus titer for each virus strain. 4. Incubate for 1 h at 28 °C under non CO2 atmosphere condition.
5. Remove virus inoculum and add 25 ml RPMI 1640 medium (2% FBS) to the 175 cm 2 flask.
6. Incubate for 4-7 days at 28 °C under non CO2 atmosphere condition.
Note: Cytopathic effect is observed depending on virus strain (seen in EDEN2 infection but not in EDEN1 or S221 infection). Check virus titer in the supernatant at different time point to determine the optimal day to obtain high virus titer (refer to Procedure B on how to determine virus titers). Incubation periods are 5 days for EDEN2 and S221, and 7 days for EDEN1.
www.bio-protocol.org/e2040 10. Rinse the plate with copious volume of water in a container. Shake the plate robustly to remove methyl-cellulose medium completely.
11. Add 1-3 drops of 1% crystal violet into each well and stain for 2 min.
12. Rinse the plate with copious volume of water in a container and shake the plate to remove excess water.
13. Dry the plate out and count the number of plaques to determine virus titer.
Caluculation of plaque forming units (pfu):
Virus titer (pfu/ml) = average number of plaques/200 μl inoculum x 1,000 μl x dilution factor www.bio-protocol.org/e2040 6. Filter the supernatant through a 0.2 μm membrane filter unit.
7. Load the 4G2 supernatant onto a 5 ml Protein G column pre-equilibrated in pH 7.2 PBS.
Note: 4G2 antibody is purified using the AKTApurifier. Refer to the manufacturer's instruction guides regarding sample loading specifications.
8. Wash the column with PBS using 5x the column volume (i.e., 25 ml).
9. Prepare a 96-well block containing 60 μl 1 M Tris-HCl.
Note: The standard ratio of Tris-HCl to glycine (100:6) for neutralization is subjected to change depending on the concentration of buffers prepared. Volume of Tris-HCl to be added required for neutralization (pH 7) can be adjusted by pH paper testing.
10. Elute antibodies using 100% 0.1 M glycine and collect 1 ml fractions into the wells of the block.
Note: Check the purity of the antibody by running a SDS-PAGE.
11. Select fractions of high purity and collect into a dialysis membrane, and then dialyse against PBS overnight.
12. Quantitate the concentration of the purified antibody using NanoDrop. (Watanabe et al., 2016) together with the pioneering mouse model using mouse-adapted DENV2 (S221 strain) (Zellweger et al., 2010 ). 6. Observe mouse disease status and survival rate until day 10 post-infection. (Zellweger et al., 2010; Watanabe et al., 2016) .
D. DENV infection in AG129 mice and measurement of viremia
Note: Infectivity of DENV in AG129 mice differs among virus strains. DENV2 clinical strains are generally more infectious than DENV1 clinical strains in the mice (our unpublished observation).
Infection in the presence of DENV-specific antibodies (ADE condition) can enhance the infection level and make it possible to induce mortality. Here we describe the methods for two successful mouse models of clinical isolates of DENV1 (EDEN1 strain) and DENV2 (EDEN2 strain)
Note: Mice usually succumb to infection by day 5 post-infection accompanied with a severe form of human DHF/DSS-like diseases
7. Add 10 μl of 1% (wt/vol) EDTA (in PBS) into each 1.5 ml Eppendorf tube for blood collection.
Hold the mouse vertically with the head tilted back and collect approximately 100 μl of blood from facial vein using a 27 G needle (final 0.1% EDTA).
Note: It is possible to collect 100 μl of blood from each mouse on 10 consecutive days.
8. Centrifuge the blood samples at 13,500 x g for 3 min.
9. Collect serum and store at -80 °C until use.
10. Collect 20 μl of each serum sample and mix with 120 μl PBS.
11. Extract RNA from serum using QIAamp Viral RNA Mini Kit according to the manufacturer's instruction.
12. Make 20 μl reaction mixture (4 μl RNA plus 16 μl PCR reagent mixture) using the qScript One-
Step qRT-PCR Kit. Prepare standard curves with plasmid DNA ranging from 10 7 to 10 1 copies/4
µl. Perform quantitative RT-PCR reactions in duplicate in Bio-Rad Real-time thermal cycler CFX96 according to the manufacturer's instruction.
13. Run the qPCR using the following program www.bio-protocol.org/e2040 Store the solution at room temperature
